Multimorbidity Management Supported by a Digital Platform

Sponsor
Universidade Nova de Lisboa (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05593835
Collaborator
Administração Regional de Saúde de Lisboa e Vale do Tejo, Portugal (Other), Universidade Lusófona de Humanidades e Tecnologias (Other), NOVA Medical School (Other), NOVA School of Science and Technology ı FCT NOVA (Other), University Hospital, Geneva (Other)
1,380
2
36

Study Details

Study Description

Brief Summary

This study aims to assess whether the use of the METHIS digital platform using a patient-centered approach contributes to an improvement in the quality of life, mental health and physical activity of patients with multimorbidity followed up in Primary Health Care. Practices will be randomly allocated between: providing access to consultations through the METHIS platform (intervention) or following patients by the traditional method (control). They will complete questionnaires on quality of life, mental health and report the number of steps taken, at the beginning and end of the study.

Condition or Disease Intervention/Treatment Phase
  • Device: METHIS Platform
  • Other: Goal-Oriented Care Training Program
N/A

Detailed Description

A superiority, cluster randomised trial will be conducted at Primary Health Care Practices (1:1 allocation ratio). All public practices in the Lisbon and Tagus Valley Region, Portugal, not involved in a previous pilot trial, will be eligible. The intervention combines a training programme and a customised Information System (METHIS). Both are designed to help clinicians to adopt a Goal-Oriented Care Model approach and to encourage patients and carers to play a more active role in autonomous healthcare.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1380 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Cluster Randomised TrialCluster Randomised Trial
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Protocol for a Cluster Randomised Trial of a Goal-Oriented Care Approach for Multimorbidity Patients Supported by a Digital Platform
Anticipated Study Start Date :
Jan 2, 2023
Anticipated Primary Completion Date :
Jun 30, 2025
Anticipated Study Completion Date :
Jan 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: METHIS Intervention

The METHIS intervention will consist of two components. The first component is a Goal-Oriented Care (GOC) Training Program for health professionals. The training program will include the concept of personalised care, methods of goal elation, implications of GOC in healthcare practice, and how METHIS platform can be used to support the application of GOC. The training will be implemented through a blended-learning, continuous education program that will be credited by Nova University of Lisbon. The second component is a GOC information system. This will be the digital platform METHIS, which will be designed to nudge clinicians to adopt a GOC and to encourage patients and caregivers to take an active role in healthcare. The investigators will adapt an existing platform that was developed for a pilot study during the COVID-19 pandemic, that promotes care coordination, optimises disease prioritisation, and patient self-management.

Device: METHIS Platform
The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
Other Names:
  • Goal-Oriented Care Information System
  • GOC Information System
  • Other: Goal-Oriented Care Training Program
    The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
    Other Names:
  • GOC Training Program
  • No Intervention: Control

    The control group in this trial will be the best usual care, using the standard Electronic Health Records available to the practice. Our understanding of what "best usual care" is for people with multimorbidity is informed by qualitative research in an earlier stage of this project. Our results suggest that healthcare professionals often provide disease-driven care. When faced with multiple healthcare problems, they prioritise based on 1) patient complaints; 2) which condition is less well controlled; or 3) which condition is more likely to adversely impact on patient Health Related-Quality of life. General practitioners and primary care nurses are often not familiar with the Goal-Oriented Care model. However, they already try to implement some of its principles such as identifying patient goals and supporting shared decision making.

    Outcome Measures

    Primary Outcome Measures

    1. Health related quality of life [Participants will be asked to fill in the SF-12 questionnaire at baseline and at 12 months.]

      Participants will be asked to fill in the SF-12 questionnaire which generates a physical component score (PCS) and a mental component score (MCS). The primary outcome will be the mean difference in the variation (delta) of the PCS of SF-12 between baseline and 12 months. The SF-12 can be filled in 2-4 minutes, and it is validated for the Portuguese population. Minimum important differences validated across large populations and multiple disease categories are a change in between 2 and 3 points from the population mean of 50.

    Secondary Outcome Measures

    1. Mental health status [Participants will complete the HADS-A and HADS-D questionnaire at baseline and at 12 months.]

      Participants will be asked to complete the Hospital Anxiety and Depression Scale questionnaire (HADS-A and HADS-D, respectively). The investigators will calculate the mean difference in the variation (delta) in HADS-A and HADS-D between baseline and 12 months. Although HADS was designed for inpatients it was posteriorly validated in the primary care outpatient setting. A minimum important difference of 1.5 has been reported in other chronic disorders.

    2. Physical activity [Participants will wear the SmartBand for 12 months.]

      Physical activity will be monitored through the number of steps walked daily. To assess the number of steps per day, a smart band with a triaxial Accelerometer will be used in both arms of the trial. Although traditional step counters use pedometers to detect daily step counts, accelerometers are more accurate and sensitive to lower force accelerations (e.g., slow walking) being considered the current standard for collecting physical activity data. Sedentary older adults and individuals living with disability and chronic illness benefit from a physically active lifestyle, with approximately 4,600- 5,500 daily steps. The lowest median values for steps/day found is in disabled older adults (1214 steps/day) and by people living with COPD (2237 steps/day).

    3. Number of serious adverse events (clinician-reported) [Family physicians will be asked, at 6 and 12 months after randomization, to check the life status of enrolled patients and whether patients in the trial were admitted to a hospital or had a visit to an emergency service since the randomization date.]

      These will be the safety outcomes chosen for this trial. In both trial arms, data about patient mortality will be collected and combined with data on occurrence of emergency department visits and hospital admissions as a proxy for serious adverse events. This information is available through the Portuguese common EHR. Due to legal requirements, after death, the information about hospital admissions and other contacts with healthcare organisations ceases to be available to the attending physician.

    4. Number of potentially missed diagnoses (clinician-reported) [Potentially missed diagnoses will be reported 6 months after the intervention phase. In this way a compromise between avoiding recall bias and allowing enough time for a missed diagnosis to become clinically apparent is achieved.]

      These will be a second safety outcome. The investigators will ask clinicians in the intervention arm if they are aware of any serious diagnosis that might have been missed due to the intervention.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • community-dwelling people

    • aged 50 or older

    • with complex multimorbidity (co-occurrence of three or more chronic conditions affecting three or more different body systems)

    • with access to an Internet connection and a communication technology device

    Exclusion Criteria:
    • inability to: provide informed consent, to read or write, inability to access an email or electronic device, even when helped by an informal caregiver

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Universidade Nova de Lisboa
    • Administração Regional de Saúde de Lisboa e Vale do Tejo, Portugal
    • Universidade Lusófona de Humanidades e Tecnologias
    • NOVA Medical School
    • NOVA School of Science and Technology ı FCT NOVA
    • University Hospital, Geneva

    Investigators

    • Principal Investigator: Luís V. Lapão, PhD, Universidade Nova de Lisboa

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Universidade Nova de Lisboa
    ClinicalTrials.gov Identifier:
    NCT05593835
    Other Study ID Numbers:
    • METHIS_CRTMB2022
    First Posted:
    Oct 25, 2022
    Last Update Posted:
    Oct 25, 2022
    Last Verified:
    Oct 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Universidade Nova de Lisboa
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 25, 2022